MRK Research Update — August 28, 2026
Updated Thesis
Merck is a diversified global biopharmaceutical and animal-health company whose high-quality commercial infrastructure, regulatory capabilities, oncology franchise, vaccine portfolio and animal-health business support a durable intangible-asset moat, but its earnings profile is currently distorted by acquisition charges and its revenue base remains highly concentrated in KEYTRUDA. In Q2 2026, revenue grew 5.1% year over year to $16.607 billion, led by $8.366 billion of KEYTRUDA and KEYTRUDA QLEX sales, while WINREVAIR grew 75%; however, earnings declined 130.2% year over year in the most recent quarter amid large acquisition-related charges. The business generated TTM gross, operating and net margins of 75.4%, 16.7% and 4.8%, respectively, but the 4.8% net margin and 116.5x trailing P/E reflect unusual charges rather than normalized profitability.
The investment grade as of this refresh is C — average business quality. High-tier business, expensive-tier valuation, with 11.9% downside to $131.77 fair value.
Grade Change
In this research cycle, the investment grade for Merck & Co., Inc. moved from D to C. High-tier business, expensive-tier valuation, with 11.9% downside to $131.77 fair value.
Key Metrics at a Glance
- Revenue growth: +5.1% year over year
- Net margin: 4.8%
- Fair value upside: -11.9% to our estimate of $132
Current price: $149.54
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Merck & Co., Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MRK research →](/stocks/MRK)